Related Experiment Video
Updated: Jun 25, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Drug interaction between maribavir and rifampin: a case report
Minh P Lê1, Thibaut D'Izarny-Gargas2, Louise Chantelot3
1Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France; AP-HP, Hôpital Bichat, Service de Pharmacologie, Paris, France.
This study explores managing drug-resistant Cytomegalovirus (CMV) infections in transplant patients. It highlights how adjusting maribavir dosage with therapeutic drug monitoring can overcome drug-drug interactions with rifampin.
Area of Science:
- Pharmacology
- Infectious Diseases
- Transplantation
Background:
- Cytomegalovirus (CMV) infection poses significant risks for immunocompromised individuals, especially transplant recipients.
- Drug-resistant CMV strains and ganciclovir toxicity necessitate alternative treatments.
- Maribavir offers a novel approach by inhibiting the CMV UL97 protein kinase, effective against resistant strains.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Inhibitors of Viral Protein Synthesis
